|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||366.458 g/mol g·mol−1|
|3D model (JSmol)|
Liafensine (BMS-820836) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) which was under development by Bristol-Myers Squibb for the treatment of major depressive disorder. Though it demonstrated comparable effectiveness to escitalopram and duloxetine in phase II clinical trials, development was terminated in 2013 because liafensine failed to show superior effectiveness relative to these drugs, a decision that was made likely based on its increased capacity for side effects as well as potential for abuse.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|